Announcements Trials
Browse Landscape

Phase

Phase 2 34Phase NA 32Phase 1 30Phase 1/2 18Phase EARLY_PHASE1 10Phase 3 3Phase 4 2Phase 2/3 2

Status

Recruiting 10Completed 10Unknown 7Terminated 5Active not recruiting 3Withdrawn 2Not yet recruiting 2Suspended 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 6Carcinoma, Hepatocellular 5Head and Neck Neoplasms 4Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasms, Squamous Cell 2Glioblastoma 2Colonic Neoplasms 2Uterine Cervical Neoplasms 1Urinary Incontinence 1Tuberous Sclerosis 1Sarcoma 1Recurrent respiratory papillomatosis 1Recurrence 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Postoperative Complications 1Papillomavirus Infections 1Papilloma 1Ovarian Neoplasms 1Orgasm 1Oligodendroglioma 1Neoplasms 1Neoplasm Metastasis 1Myasthenia Gravis 1Melanoma 1Medication Adherence 1

Interventions

methylnaltrexone 1Mirtazapine 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Withdrawn × Pancreatic Neoplasms × Clear all
NCT04083651 2021-05-07

A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer

Bausch Health Americas, Inc.

Phase 2/3 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

NCT01598584 2015-09-28

Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2/3 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡